收购战略 - 公司收购行为旨在支持其开发糖尿病、肥胖症及其相关并发症治疗药物的战略 [1]

Telangana industries & IT minister Sridhar Babu (L) and CM A Revanth Reddy (C) with Patrik Jonsson, executive VP and president of Lilly International, Eli Lilly and Co in HyderabadTelangana chief minister A Revanth Reddy and industries minister D Sridhar Babu met Lilly's global team led by Patrik Jonsson, executive vice president and president Lilly International, Eli Lilly and Company at the integrated command control centre in Hyderabad on Monday. Revanth said despite Lilly being wooed by multiple states, ...

Eli Lilly to inject $1 billion in new contract manufacturing facilities in India; to set up new manufacturing & quality hub in HyderabadThe new manufacturing and quality hub in Hyderabad will offer advanced technical capabilities and oversight for its contract manufacturing network across India, Lilly said on Monday.The US pharma giant said it will immediately begin recruitments for the new facilities with openings across roles such as engineers, chemists, analytical scientists, quality control and assuranc ...

投资评级与价格目标 - 贝伦伯格银行将诺和诺德评级从持有上调至买入 并将目标价设定为42500丹麦克朗 意味着潜在上涨空间为20% [1] - 此次评级上调是在公司股价在2024年中见顶后经历一系列指引下调之后进行的 标志着市场预期的重置 [2] 公司前景与战略 - 贝伦伯格银行认为市场预期重置为围绕公司增长前景 估值和战略催化剂进行更具建设性的讨论打开了大门 [2] - 公司在新任首席执行官领导下有望重获增长动力 在肥胖症药物市场的战略胜利可能带来积极惊喜 [3] - 研究机构改变了行业偏好 更青睐诺和诺德而非其竞争对手礼来公司 [3] 公司业务聚焦 - 诺和诺德是一家医疗保健公司 主要开发并提供针对严重慢性疾病的创新药物和给药系统 [4] - 公司业务重点领域包括糖尿病 肥胖症 以及罕见的血液和内分泌疾病 [4]